Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2300780 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Yoshihiro Oya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Autoimmune Diseases, Department of Clinical Research, National Hospital Organization Chibahigashi National Hospital, Chiba City, Chiba,…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Dendritic Cells, Isoantigens, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: NIAID NIH HHS, NIAID.
Abstract (Originalsprache)
Foxp3+ T regulatory (Treg) cells prevent allograft rejection and graft-versus-host disease. Although polyclonal Tregs have been used both in animal models and in humans, the fine specificity of their suppressive function is poorly defined. We have generated mouse recipient-derived alloantigen-specific Tregs in vitro and explored the fine specificity of their suppressive function and their mechanism of action in vitro and in vivo. In vitro, when alloantigen and peptide Ag were both presented on the same dendritic cell, both responses were suppressed by iTregs specific either for the alloantigen or for the peptide Ag. In vivo, iTreg suppression was limited to the cognate Ag, and no bystander suppression was observed when both allo-antigen and peptide Ag were present on the same dendritic cell. In vitro, alloantigen-specific Tregs captured cognate MHC but failed to capture noncognate MHC. Our results demonstrate that a polyclonal population of iTregs generated from naive T cells can mediate highly specific function in vivo and support the view that Treg therapy, even with unselected polyclonal populations, is likely to be target antigen-specific and that bystander responses to self-antigens or to infectious agents are unlikely.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Autoimmune Diseases, Department of Clinical Research, National Hospital Organization Chibahigashi National Hospital, Chiba City, Chiba, Japan.
- Laboratory of Immune System Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
- Department of Rheumatology, Allergy and Clinical Immunology, National Hospital Organization Chibahigashi National Hospital, Chiba City, Chiba, Japan.
- Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University Hospital, Chiba City, Chiba, Japan.
ORCID-Profile: Yoshihiro Oya, Yasuyo Tanaka, Takuya Nakazawa, Ethan M Shevach
Förderung
- NIAID NIH HHS
- NIAID
Zitieren
APA
Oya, Y., Tanaka, Y., Nakazawa, T., Matsumura, R., Glass, D. D., Nakajima, H., & Shevach, E. M. (2024). Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300780
Vancouver
Oya Y, Tanaka Y, Nakazawa T, Matsumura R, Glass DD, Nakajima H, et al. Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300780
BibTeX
@article{Oya2024,
author = {Oya, Yoshihiro and Tanaka, Yasuyo and Nakazawa, Takuya and Matsumura, Ryutaro and Glass, Deborah D and Nakajima, Hiroshi and Shevach, Ethan M},
title = {Polyclonally Derived Alloantigen-Specific T Regulatory Cells Exhibit Target-Specific Suppression and Capture MHC Class II from Dendritic Cells},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2300780}
}
EUVIMED